Direct-to-consumer virtual health company Ro announced Monday it’s $200 million Series C funding round. With these additional funds, the company is now valued at $1.5 billion.
The existing investor, General Catalyst, led the round with participation from FirstMark Capital, Torch, SignalFire, TQ Ventures, Initialized Capital, 3L, BoxGroup and the Chernin Group. Ro has raised $376 million since its...
Ro, a direct-to-consumer virtual health startup best known for its sexual health products, is dipping into the dermatology space. Patients will now be able to use the service for prescription products that include eczema treatment, medical-grade antiperspirant, and prescription dandruff shampoo.
The company will also be rolling out a “nightly defense skincare” that is a custom prescription...
Direct-to-consumer virtual health company Ro is now offering allergy care. The launch means that users of Roman and Rory will be able to get prescription allergy medications through the platform’s telemedicine model.
While the company said that the new service will not be treating food allergies or uncontrolled asthma, it will cover seasonal allergies, including conditions like hay fever. ...
Direct-to-consumer virtual health company Ro launched a new health information platform dubbed Health Guide.
Currently the platform covers sexual health, hair loss, weight management, diabetes, and men’s health. However, a representative from the company said that in the future, the plan is to expand the offerings to not only cater to male users, and to include more conditions.
The company,...
There are some striking similarities between mail-order sexual health companies Ro and Hims: Both started out focused on men’s sexual health, both employ telemedicine and if you ride the subway in a major city you’ve probably seen their advertisements.
But things are getting heated this week after Hims launched an updated version of its platform. On Tuesday, Ro cofounder Zachariah Reitano...
Direct-to-consumer telemedicine services have attracted plenty of attention from investors and patients alike, due in part to their lower costs and ease of use. From a medical standpoint, however, these business models introduce a number of departures from traditional care that deserve serious concern and investigation, argue the authors of an editorial published Friday in JAMA.
“DTC telemedicine...
Photo Credit/ Ro, press kit
Ro — the company which made its mark with a men’s health platform focused on erectile dysfunction called Roman — has landed an additional $85 million in Series B financing, according to a source at TechCrunch.
When MobiHealthNews reached out, the company declined to comment on this funding.
WHAT THEY DO
Ro made a name for itself in the digital health world with its online platform that...
What happened
Ro—company previously known for its online men's health platform focused on erectile dysfunction, Roman— announced that it landed $88 million, this time to work on an addiction cessation platform. This round was led by FirstMark Capital with participation from SignalFire, Initialized Capital, General Catalyst, Slow Ventures, Sinai Ventures, Torch Capital, BoxGroup, Tusk Ventures and...
Roman, an online men's health platform initially focused on erectile dysfunction, launched this week with $3.1 million in funding. General Catalyst led the round, with participation from Initialized Capital, Box Group, and Slow Ventures. The company also announced a number of angel investors including Casper CEO Philip Krim, Bark CEO Matt Meeker, WayUp CEO Liz Wessel, Code Academy CEO Zach Sims,...
